Summarize This Guide with AI
The page title, key topics and source link are passed to your selected tool in a prepared prompt.
On this page
Blood clots with an inability to pass urine, heavy bleeding or marked weakness need urgent medical assessment. Visible blood still needs urological evaluation if it happened only once and then stopped. Pain is not required for the finding to matter.
Blood in urine is called haematuria. Urine may appear pink, red, dark red or tea-coloured. In other people, the urine looks normal and red blood cells are found only by laboratory examination. Possible causes include infection, stones, prostate or urethral problems, injury, recent procedures, kidney disease and urinary tract tumours. Haematuria alone is not a cancer diagnosis, but unexplained visible bleeding should not be dismissed without assessment.
Visible blood and microscopic blood
Bleeding can arise anywhere from the kidneys to the urethra, where urine leaves the body. The ureters, bladder, prostate and bladder outlet may be considered during assessment. The colour alone cannot establish that blood came from the kidney, prostate or bladder. General urinary concerns are discussed in the men’s urology guide.
Visible haematuria means blood is noticed without a microscope. Clots may also appear. The amount of colour does not reliably measure the seriousness of the cause: a small visible episode can need investigation, while a striking colour change may have a different explanation.
Microscopic haematuria means red blood cells are identified by microscopy even though urine appears normal. The AUA/SUFU framework defines it using the red-cell count in a properly collected sample. A dipstick reporting “blood positive” is not identical to that finding. Dipsticks can react to haemoglobin or myoglobin as well as red cells, so microscopic confirmation may be needed. AUA/SUFU microhaematuria guidance
Red or brown urine is not always blood. Foods such as beetroot, food colouring, certain medicines, concentrated urine and pigments may alter its appearance. Conversely, a small quantity of blood may not change the colour. If the explanation is uncertain, a urine examination helps distinguish the possibilities rather than relying on appearance.
Causes considered during assessment
Infection and inflammation can cause blood with burning, urinary frequency, urgency, lower abdominal discomfort or fever. These symptoms may prompt urinalysis and, when indicated, a culture. Blood should not automatically be labelled an infection or treated with antibiotics without assessment. Persistent or recurrent blood after treatment needs attention. The guide to burning when urinating explains the different urine and infection tests.
Kidney and urinary tract stones can cause haematuria. Flank pain spreading towards the groin, nausea or urinary symptoms may accompany it. Pain does not prove a stone, and an absence of pain does not exclude another condition requiring investigation. A history of stones is relevant but should not replace assessment of a new bleeding episode.
Prostate enlargement, prostate or urethral inflammation and structural problems in the lower urinary tract can also be associated with bleeding. Weak flow, hesitancy, frequency or getting up at night may coexist. These findings do not establish the prostate as the source. Prostate-related urinary symptoms are considered alongside the bleeding history.
Injury to the kidney, pelvis, penis, perineum or urethra can cause urinary blood. Catheterisation, cystoscopy, biopsy and some other procedures may cause temporary bleeding. After an injury, inability to urinate, blood at the penile opening, marked genital or pelvic swelling or severe pain need urgent assessment. After a procedure, follow the treating team’s specific instructions about expected bleeding and when to seek help.
Medical kidney conditions, including some glomerular diseases, are another possible cause. Significant protein in the urine, reduced kidney function, high blood pressure or body swelling may warrant nephrology assessment. This does not automatically remove the need for a urological evaluation when that is also indicated.
Blood-thinning medicines can make bleeding more likely or more noticeable. Their use is not a sufficient reason to skip investigation. Do not stop an anticoagulant or antiplatelet medicine yourself. Tell the clinician its name, dose and why it was prescribed; any medication change needs to be coordinated with the clinician responsible for it.
Urinary tract tumours are among the possible causes. Painless visible blood deserves assessment as well as painful bleeding. Neither a symptom list nor an online percentage determines the cause in an individual. The purpose of investigation is to establish which explanation fits the history and findings, without assuming either cancer or harmlessness.
One episode that has already stopped
Visible blood can be intermittent. The fact that the next urine looks normal does not establish that the cause has resolved. An unexplained episode in an adult should therefore be reported even if it was brief and has not recurred. Tell the doctor when it happened, whether there were clots and whether it followed an injury, exercise or a recent procedure.
Do not assume that sexual activity or exercise explains repeated visible bleeding. If a temporary explanation is considered, the follow-up plan should make clear how resolution will be checked and what would require further investigation. When blood was attributed to an infection, confirming that it has disappeared after treatment may be part of the assessment.
Information to bring to the consultation
Describe whether you saw blood directly or only received a laboratory result. Say whether the whole stream changed colour, whether clots occurred and whether there was pain, fever, burning or difficulty passing urine. Include the duration, recurrence and any relationship to a recent operation, catheter, cystoscopy or injury.
Bring a list of medication, including blood thinners, and previous urine tests, ultrasound or CT reports with their dates. Smoking history, earlier stones or urinary disease and relevant family history help guide risk assessment. The first urology appointment guide explains how existing records can be used during the visit.
If the blood was seen during ejaculation rather than in urine, mention that distinction. Blood in semen follows a different assessment, although both findings can occur together. Focusing on one should not leave the other unreported.
Selecting the investigations
The same package is not appropriate for everyone. Visible versus microscopic blood, age, smoking and other risks, kidney function, accompanying symptoms and previous results influence the plan. Initial urine microscopy helps confirm red cells and assess accompanying findings such as protein or infection markers. Culture is considered when infection is suspected; it is not required automatically for every case of haematuria.
Blood tests may include a blood count, creatinine and other tests chosen for the presentation. Ultrasound gives information about the kidneys and bladder, but it does not show every possible cause. Selected patients need more detailed upper urinary tract imaging, such as CT urography. Every finding of microscopic blood does not automatically require a CT scan.
Cystoscopy uses a thin optical instrument to examine the inside of the bladder and urethra. It may be planned when the bleeding history or risk assessment makes direct inspection appropriate. EAU guidance explains that suspected bladder tumours cannot be assessed by replacing cystoscopy with urine cytology or another non-invasive test alone. EAU diagnosis guidance
Urine cytology and urinary tumour-marker tests are not routine first tests for every patient. Their role depends on risk and the question being investigated. Ask what each investigation is intended to answer and how its result would change the next step. A normal ultrasound does not necessarily settle a question that requires examination of the bladder lining.
Why microscopic blood is assessed by risk
The AUA/SUFU 2025 update uses a risk-based framework to determine the intensity of microscopic haematuria evaluation. Age, smoking history, the degree and persistence of red cells, previous visible haematuria and other urinary tract risks are considered together. AUA/SUFU 2025 update
A lower-risk microscopic finding and recurrent visible bleeding with clots should not be managed as though they were the same presentation. Risk-based evaluation is not a reason to dismiss unexplained visible blood with a repeat dipstick alone. The American College of Physicians advice on haematuria also addresses investigation of unexplained bleeding.
Urology commonly evaluates visible haematuria and microscopic blood thought to arise from the urinary tract. Nephrology may also be involved when protein loss, impaired kidney function or other findings suggest medical kidney disease. Some people need both specialties, with the plan based on what each assessment is intended to establish.
When urgent care is needed
Seek urgent help for clot-related inability to urinate, heavy bleeding with marked weakness or severe symptoms after urinary or genital injury. Fever with severe flank pain, or bleeding accompanied by feeling seriously unwell, also needs prompt assessment. A painful full bladder with no urine output is not something to manage at home while awaiting a routine reply.
Do not start antibiotics or stop prescribed blood thinners on your own. Do not wait through severe or repeated bleeding on the assumption that you are passing a stone. Photographs of urine cannot reliably diagnose the source. A short description of the timing and accompanying symptoms, together with existing test results, helps the medical team determine the appropriate assessment.
For visible blood without an emergency feature, you can request a urology assessment without waiting for another episode. Bring the medication list and previous tests. If clots prevent urination or bleeding is heavy, seek urgent care instead of waiting for a contact-form response.
Sources7 sources
Barocas DA, et al. · The Journal of Urology · 2025
Updates to Microhematuria: AUA/SUFU Guideline (2025)DOI: 10.1097/JU.0000000000004490PubMed: 40013563
Barocas DA, et al. · The Journal of Urology · 2020
Microhematuria: AUA/SUFU GuidelineDOI: 10.1097/JU.0000000000001297PubMed: 32698717
European Association of Urology · 2026
Non-muscle-invasive Bladder Cancer Guidelines — DiagnosisNational Institute for Health and Care Excellence · 2026
Kidney cancer QS215 — Quality statement 1: Suspected cancer pathway referralNational Institute for Health and Care Excellence · 2026
Suspected cancer: recognition and referral — recommendations organised by site of cancerNielsen M, et al. · Annals of Internal Medicine · 2016
Hematuria as a Marker of Occult Urinary Tract Cancer: Advice for High-Value Care From the American College of PhysiciansDOI: 10.7326/M15-1496PubMed: 26810935
HealthTürkiye · 2026
Urology